(MENAFNEditorial) NEW YORK, Sept. 19, 2017 /PRNewswire/ --Harwood Feffer LLP () is investigating potential claims against the board of directors of Ubiquiti Networks, Inc. ("Ubiquiti" or the "Company") (NASDAQ: ) concerning whether the board has breached its fiduciary duties to shareholders.
On September 18, 2017, Citron Research published a report alleging that the Company is a "total fraud." According to the report, the Company overstated the actual number of its registered users and concealed that it does much of its business in countries under sanction by the U.S. government.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Ubiquiti shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212) 935-7400
Email:
Website:
Follow us on Twitter:
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website () for more information about the firm.
The law firm responsible for this advertisement is Harwood Feffer LLP (). Prior results do not guarantee or predict a similar outcome with respect to any future matter.
View original content with multimedia:
SOURCE Harwood Feffer LLP
MENAFN1909201700701241ID1095879546
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.